A Study to Evaluate the Efficacy and Safety of CAM-3001 (Drug) in Subjects with Rheumatoid Arthritis

Inclusion Criteria

• - Age 18 through 80 years (20 to 75 years in Japan)
• - Written consent
• - Diagnosis of adult onset Rheumatoid Arthritis (RA) of at least 3 months duration as defined by the 1987 American College of Rheumatology (ACR) classification criteria (Arnett et al, 1988)
• - Treatment with methotrexate at a stable and tolerated doses
• - Positive anti-cyclic citrullinated peptide (CCP) immuno-globulin G antibodies (more than [>] 5 international unit per milliliter [IU/mL]) and/or rheumatoid factor (RF >14 IU/mL) at screening
• - Received more than or equal to (>=) 5 milligram (mg) per week folic acid as a single or divided dose during the study.